Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

July 22, 2004 Approval Letter - Abbott HIVAB HIV-1/HIV-2 (rDNA) EIA

Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448

July 22, 2004

Submission Tracking Number (STN): BL 103385/5004

Matthew E. Klamrzynski
Abbott Laboratories
100 Abbott Park Road
Abbott Park, IL 60064-3500

Dear Mr. Klamrzynski:

Your request to supplement your Biologics License Application for Human Immunodeficiency Virus Types 1 and 2/Enzyme Immuno Assay (EIA)/Recombinant)to allow a labeling change for the Abbott HIVAB HIV-1/HIV-2 (rDNA) EIA, to extend the indications for use to include cadaveric serum specimen testing., has been approved.

This information has been placed in your biologics license file. Please keep a copy of this letter available for review at the time of FDA inspections.

Sincerely yours,

--- signature ---

Hira L. Nakhasi, Ph.D.
Division of Emerging and Transfusion Transmitted Diseases
Office of Blood Research and Review
Center for Biologics Evaluation and Research

Page Last Updated: 08/30/2010
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English